EU Streamlines Medical Device Rules: Less Burden, More Innovation for MDR/IVDR
Country: European Union
Notification Date: 2026-01-16
The European Union has notified the WTO of proposed amendments to its Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR). This initiative, G/TBT/N/EU/1184, aims to simplify rules, reduce administrative burdens on manufacturers, and enhance the predictability and cost-efficiency of certification procedures, all while maintaining high levels of public health protection and patient safety. It follows a targeted evaluation of the existing framework by the European Commission in 2024/25.
Key Details- Country: European Union
- Document Symbol: G/TBT/N/EU/1184
- Notification Date: 2026-01-16
- Comment Deadline: Not specified in notification
- Effective Date: To be determined (staggered application from entry into force, 6 months, 12 months, 3 years, and 5 years after publication in the Official Journal)
The proposal introduces significant revisions to the EU's medical device and in vitro diagnostic regulations. Key simplifications include more flexible qualification requirements for Persons Responsible for Regulatory Compliance (PRRC) and replacing maximum five-year certificate validity with periodic, risk-proportionate reviews. The framework expands acceptable clinical evidence to include non-clinical data and promotes in silico testing, while establishing proportionate requirements for "well-established technology devices."
Administrative burdens are reduced by streamlining repackaging/relabelling rules, narrowing the scope for Summary of Safety and Clinical Performance, and reducing the frequency of Periodic Safety Update Reports. Reporting timelines for non-public health serious incidents are extended to 30 days. The proposal also adapts conformity assessment for breakthrough and orphan devices, enabling priority review and rolling assessments with expert panel advice.
Digitalisation is a core theme, allowing electronic declarations of conformity, digital labels, and electronic submission of documents to Eudamed. Coordination between national competent authorities, the Commission, and Notified Bodies is enhanced, with an expanded role for expert panels providing scientific and technical advice, and EMA offering support. Fees for notified bodies will see reductions for micro, small, and orphan device manufacturers. The proposal integrates new cybersecurity reporting requirements for connected devices and promotes international reliance mechanisms.
Impact Assessment- Which products or sectors are affected: This proposal impacts all medical devices and in vitro diagnostic medical devices, particularly manufacturers (especially SMEs), notified bodies, distributors, healthcare institutions, and patients in the EU. International suppliers to the EU market will also be affected.
- Potential impact on international trade: Expected outcomes include increased competitiveness for the EU medical technology sector and smoother market access for innovative and niche devices, both domestic and international. The promotion of international cooperation and reliance mechanisms should reduce regulatory hurdles for non-EU manufacturers.
- Compliance requirements for exporters: Exporters to the EU must review new requirements for PRRC, clinical evidence, and digital submission formats. Adapting to streamlined conformity assessment procedures and new cybersecurity reporting obligations will be critical for maintaining market access.
- Market access implications: The changes aim to facilitate market entry for new, innovative, and orphan devices through more proportionate and cost-efficient conformity assessments. Extended transitional periods for certain legacy devices will help ensure continued availability. Conclusion
The EU's proposed revisions to its medical device regulations represent a significant effort to refine and future-proof the framework. By prioritizing simplification, proportionality, and digitalisation, these amendments seek to reduce burdens, enhance innovation, and ensure the continued availability of safe medical devices. Companies operating in or exporting to the EU must proactively assess these changes to maintain compliance and leverage new opportunities in a more efficient regulatory landscape.
0 Comments